Baird sees Jazz study failure as positive for rival Praxis (NASDAQ:PRAX)
2024-06-21
duoogle Baird said it believes the recent Phase 2 study failure for Jazz Pharmaceuticals’ (JAZZ) drug suvecaltamide has favorable readthrough to Praxis Precision Medicines’ (NASDAQ:PRAX) drug ulixacaltamide in the treatment of essential tremor. The investment firm said Jazz’s data has minimal impact on the probability of success for Praxis’s PhaseContinue Reading